The growing importance of real-life studies in allergen immunotherapy
Cristoforo Incorvaia1, Salvatore Barberi2, Elide Pastorello3, Giorgio Ciprandi gio.cip@libero.it4Show more: Authors information and Publication history1Cardiac/Pulmonary Rehabilitation, ASST Pini-CTO, Milan, Italy
2 Department of Paediatrics, Fatebenefratelli Hospital, Milan, Italy
3Unit of Allergology & Immunology, Niguarda Ca' Granda Hospital, Milan, Italy
4Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy
Publication History: Published online: 31 January 2019
Accepted: 11 January 2019
Received: 05 December 2018
Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.84
Abstract
Real-life studies offer the opportunity of obtaining outcomes suitable in clinical practice, as controlled trials do not mirror the real patients' population observed in clinical practice. This concept is particularly appropriate for allergen immunotherapy (AIT). Therefore, the current review will present and discuss the most recent and relevant studies published on this topic. Globally, 15 real-life studies on AIT efficacy are available until now, the total of patients amounts to 9090, with an average number of 699 patients per study. This high number significantly decrease the possibility that the observations from real-life study are casual, and confers to such studies a key role in the next years to assess issues other than efficacy and safety, especially those scantly investigated thus far.
Key words
allergen immunotherapy, respiratory allergy, real-life, real-world, clinical practice.
Cite this article as:
Incorvaia C, Barberi S, Pastorello E, Ciprandi G. The growing importance of real-life studies in allergen immunotherapy . Eur Ann Allergy Clin Immunol. 2019;51(2):115-121.doi:10.23822/EurAnnACI.1764-1489.84
FULL TEXT
